SCHEDULE 13G: State Street Corporation Discloses 4.8% Passive Stake in Neurocrine Biosciences

State Street Corporation has reported a passive beneficial ownership of 4.8% in Neurocrine Biosciences Inc., holding 4,891,137 shares of common stock as of December 31, 2024.

Summary

• State Street Corporation, a parent holding company, has filed a Schedule 13G indicating its beneficial ownership in Neurocrine Biosciences Inc.
• As of December 31, 2024, State Street Corporation beneficially owns 4,891,137 shares of Neurocrine Biosciences Inc. common stock.
• This ownership represents 4.8% of the total outstanding common stock of Neurocrine Biosciences Inc.
• State Street Corporation holds shared voting power over 4,431,623 shares and shared dispositive power over all 4,891,137 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine Schedule 13G filing by a passive institutional investor, providing factual ownership data without expressing positive or negative sentiment about the issuer's performance or outlook.

Positives

• A major institutional investor, State Street Corporation, holds a significant passive stake, indicating its inclusion in their investment portfolios.

Negatives

• The filing does not indicate any active engagement or intent to influence the company's management or strategy.

Risks

• The beneficial ownership is passive, meaning State Street Corporation does not intend to influence or change the control of Neurocrine Biosciences Inc.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Neurocrine Biosciences Inc.'s future outlook.

Management Comments

• "The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, State Street Corporation, indicating its passive investment in Neurocrine Biosciences, a biopharmaceutical company. Such filings are common for large index funds or diversified portfolios managed by institutions.

Comparison to Industry Standards

• State Street Corporation's 4.8% stake is below the 5% threshold that would trigger a more active Schedule 13D filing, consistent with its stated passive investment strategy.
• The holding is typical for a large asset manager like State Street, which often holds significant, but non-controlling, stakes across numerous publicly traded companies as part of diversified portfolios or index funds.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, potentially offering some stability or validation.
• Management: No direct impact as the stake is passive and not intended to influence control.

Next Steps

• State Street Corporation will file amendments to this Schedule 13G if its beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if its intent changes.

Key Dates

Keywords

Neurocrine Biosciences, State Street Corporation, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investor, passive investment